<DOC>
	<DOCNO>NCT00482222</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , oxaliplatin , fluorouracil , leucovorin , capecitabine , work different way stop growth tumor cell , either kill cell stop dividing . Monoclonal antibody , cetuximab , block tumor growth different way . Some block ability tumor cell grow spread . Others find tumor cell help kill carry tumor-killing substance . Giving combination chemotherapy together monoclonal antibody surgery may make tumor small reduce amount normal tissue need remove . Giving treatment surgery may kill tumor cell remain surgery . It yet know whether combination chemotherapy effective without cetuximab treat liver metastasis cause colorectal cancer . PURPOSE : This randomized phase III trial study combination chemotherapy compare well work give without cetuximab surgery treat patient resectable liver metastasis cause colorectal cancer .</brief_summary>
	<brief_title>Combination Chemotherapy With Without Cetuximab Before After Surgery Treating Patients With Resectable Liver Metastases Caused By Colorectal Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare progression-free survival patient resectable colorectal liver metastasis treat neoadjuvant adjuvant combination chemotherapy v without cetuximab . Secondary - Compare overall survival patient treat regimen . - Compare quality life patient treat regimen . - Compare cost effectiveness regimens patient . OUTLINE : This prospective , randomize , multicenter , open-label study . Patients stratify accord participate center assign chemotherapy regimen . Patients randomize 1 2 treatment arm . - Neoadjuvant therapy : - Arm I : Patients receive 1 follow chemotherapy regimen : - OxMdG : Patients receive leucovorin calcium IV 2 hour oxaliplatin IV 2 hour day 1 . Patients also receive fluorouracil IV continuously 46 hour begin day 1 . Treatment repeat every 2 week 6 course absence disease progression unacceptable toxicity . - CAPOX : Patients receive oxaliplatin IV 2 hour day 1 oral capecitabine twice daily day 1-14 . Treatment repeat every 3 week 4 course absence disease progression unacceptable toxicity . - Arm II : Patients receive 1 follow regimen : - OxMdG + cetuximab : Patients receive cetuximab IV 1-2 hour day 1 OxMdG chemotherapy arm I . Treatment repeat every 2 week 6 course absence disease progression unacceptable toxicity . - CAPOX + cetuximab : Patients receive cetuximab IV 1-2 hour day 1 , 8 , 15 CAPOX chemotherapy arm I . Treatment repeat every 3 week 4 course absence disease progression unacceptable toxicity . - Surgery : Beginning 2-6 week completion chemotherapy , patient arm undergo liver resection . - Adjuvant therapy : Beginning 4-8 week completion surgery , patient receive treatment ( OxMdG CAPOX without cetuximab ) arm I II neoadjuvant therapy . - Arm I : Treatment OxMdG repeat every 2 week 6 course treatment CAPOX repeat every 3 week 4 course absence disease progression unacceptable toxicity . - Arm II : Treatment OxMdG + cetuximab repeat every 2 week 6 course treatment CAPOX + cetuximab repeat every 3 week 4 course absence disease progression unacceptable toxicity . Quality life assess baseline , every 12 week chemotherapy , completion study treatment , every 3 month 1 year , every 6 month thereafter . Cost per life year per quality-adjusted life year assess baseline , every 12 week treatment , 3 , 5 , 10 year . After completion study treatment , patient follow every 3 month 2 year every 6 month 3 year . Peer Reviewed Funded Endorsed Cancer Research UK</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically* radiologically confirm primary adenocarcinoma colon rectum Advanced and/or metastatic disease NOTE : *Liver metastasis biopsied Must potentially resectable liver metastasis present , define follow : Metachronous metastasis AND complete resection primary tumor without gross microscopic evidence residual disease ( R0 ) Synchronous metastasis AND R0 resection primary tumor &gt; 1 month study entry Synchronous metastasis sufficient evidence ( e.g. , CT scan diagnostic laparoscopy ) primary tumor liver metastases completely resected procedure resection primary tumor delay 34 month Suboptimally resectable disease ( i.e. , potentially resectable disease compromise resection margin ) No detectable extrahepatic tumor completely resect Unidimensionally measurable disease No brain metastasis PATIENT CHARACTERISTICS : WHO performance status 02 WBC ≥ 4,000/mm³ ANC ≥ 1,500/mm³ Platelet count &gt; 150,000/mm³ Bilirubin ≤ 1.25 time upper limit normal ( ULN ) Alkaline phosphatase ≤ 5 time ULN AST ALT ≤ 3 time ULN Creatinine clearance &gt; 50 mL/min OR glomerular filtration rate &gt; 50 mL/min Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception ≥ 3 month completion study treatment No psychiatric neurological condition would preclude study compliance No partial complete bowel obstruction No preexisting neuropathy &gt; grade 1 No prior concurrent malignant disease , opinion investigator , would preclude study treatment No concurrent severe uncontrolled medical illness ( include poorlycontrolled angina myocardial infarction within past 3 month ) would preclude study treatment No know hypersensitivity reaction component study drug PRIOR CONCURRENT THERAPY : No prior systemic chemotherapy metastatic disease More 6 month since prior adjuvant chemotherapy comprise fluorouracil , leucovorin calcium , capecitabine , irinotecan hydrochloride More 1 month since prior rectal chemoradiotherapy comprise fluorouracil leucovorin calcium No concurrent contraindicate medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2008</verification_date>
	<keyword>adenocarcinoma colon</keyword>
	<keyword>stage IV colon cancer</keyword>
	<keyword>adenocarcinoma rectum</keyword>
	<keyword>stage IV rectal cancer</keyword>
	<keyword>liver metastasis</keyword>
	<keyword>recurrent colon cancer</keyword>
	<keyword>recurrent rectal cancer</keyword>
</DOC>